ARMO BioSciences
575 Chesapeake Dr
Redwood City
California
94063
United States
51 articles about ARMO BioSciences
-
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
-
Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.
-
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
-
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
8/16/2018
Synthorx, Inc. today announced the appointment of Joseph Leveque, M.D., as chief medical officer.
-
Pharma a Significant Driver for Eli Lilly’s 2Q, Company Plans IPO for Animal Health Business
7/24/2018
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year. -
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
Shares of Ziopharm Oncology, Inc. are still sliding after the company announced it was pausing its planned Phase III trial for its lead gene therapy product designed to treat patients with recurrent glioblastoma (rGBM) as a monotherapy and in combination with an immune checkpoint inhibitor.
-
Only days after Eli Lilly and Company agreed to pay $1.6 billion for ARMO BioSciences, the Indianapolis-based drug company is acquiring AurKa Pharma, an oncology company.
-
Lilly Announces Agreement To Acquire ARMO BioSciences
5/10/2018
$1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types
-
Shares of Armo BioSciences have soared more than 67 percent in premarket trading after Eli Lilly announced it had struck a deal to acquire the company for $1.6 billion in an all cash deal.
-
Since Friday, the stock market has been volatile, to say the least.
-
Bay Area's ARMO BioSciences Raises $128M in IPO
1/26/2018
The offering is expected to close on January 30, 2018, subject to customary closing conditions.
-
ARMO BioSciences Files Registration Statement for Proposed IPO
1/2/2018
The number of shares to be offered and the price range for the proposed offering have not yet been determined.
-
Three biotech companies want to start out the new year with a new start.
-
ARMO BioSciences Presents Data From its Phase Ib Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017
12/11/2017
In 27 NSCLC patients who had received a median of two prior therapies, AM0010 in combination with either nivolumab or pembrolizumab induced a durable rate of tumor shrinkage of 41%.
-
ARMO BioSciences Presents Efficacy Data From its Phase Ib Trial in Patients With Metastatic Renal Cell Carcinoma at ESMO Immuno-Oncology Congress 2017
12/8/2017
ARMO BioSciences today announced additional clinical trial results on its lead investigational immuno-oncology drug AM0010 in metastatic renal cell carcinoma.
-
ARMO BioSciences Appoints Herb Cross as CFO
11/28/2017
Mr. Cross has over twenty years of experience, with executive leadership roles in both private and public biotechnology companies.
-
ARMO BioSciences Appoints Immuno-Oncology Industry Veteran Joseph Leveque, M.D., As Chief Medical Officer
10/9/2017
-
ARMO BioSciences's Phase Ib Trials Demonstrate Continued Promising Response Rates And Survival In Patients With Advanced Pancreatic Cancer, NSCLC, And RCC
9/11/2017
-
Bay Area's ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene And Google
8/29/2017